Drug intelligence / Profile preview

lipopolysaccharide from Pantoea agglomerans

Development stage: Unknown
Lead developer: Tokushima Bunri University
Administration: Oral, Transdermal, Sublingual

Overview

**Lipopolysaccharide from Pantoea agglomerans** is a component of the cell walls of the bacterium *Pantoea agglomerans*, which is symbiotic with plants like wheat. It is known for its immunomodulatory effects, particularly in activating macrophages and enhancing innate immunity. It is used in health food, skincare products for atopic dermatitis, and as an active ingredient in feeds for stockbreeding and aquaculture due to its ability to activate macrophages and improve various health conditions. Additionally, it promotes wound healing by enhancing keratinocyte migration and has been explored as a mucosal adjuvant for vaccines.

Other names: Lipopolysaccharide (LPS) from Pantoea agglomeransLPSp

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on lipopolysaccharide from Pantoea agglomerans.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lipopolysaccharide from Pantoea agglomerans.